Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.49. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| GILD | KOLD | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $49.39 |
52-Week Low | $108.22 | $13.58 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
KOLD trades at $26.915, down 1.77% today, with technical indicators showing a bullish moving average signal but overbought RSI readings. The stock is influenced by natural gas market volatility, with recent news highlighting weather-driven demand shifts and record supply/demand forecasts for 2026. Support and resistance levels are tightly clustered around $25-$29, indicating potential for near-term price swings.
Outlook remains tactical, with KOLD serving as a leveraged tool for natural gas price movements. Key opportunities include geopolitical risks and LNG demand growth, while risks involve weather volatility and production increases. Analyst sentiment is mixed, emphasizing its role as a trading vehicle rather than a long-term hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
